SAM #36C25027Q0091

Sole-source Decipher prostate genomic testing services for VA Northeast Ohio

The Department of Veterans Affairs plans to obtain prostate cancer genomic testing for the VA Northeast Ohio Healthcare System. - Agency: VA Network Contracting Office 10, on behalf of the VA Northeast Ohio Healthcare System / Cleveland VA Medical Center. - Procurement approach: Notice of intent to negotiate a sole-source contract with Veracyte, Inc.; this is not a solicitation for competitive offers. - Service: Decipher testing analyzes 22 genes in existing prostate tissue from a biopsy or surgery and produces a score assessing tumor aggressiveness and risk of progression or metastasis. - Clinical use: Testing is intended for localized, N1, or metastatic prostate cancer and is performed before radiation or hormone therapy. - Competition: Interested sources may submit capability information showing they can meet the requirement and that competition would benefit the Government. No response deadline or quantity is provided in the supplied information.

Description

Notice of Intent to Sole-Source Requirement

The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements.

The associated NAICS code for this is 334516, Size Standard is 1,000 employees. 

Product Service Code (PSC) is Q301.

The sole-source contract will be awarded to:

VERACYTE, INC

UEI: JS7GBP6LCMN6

Description of equipment requirements:

The VA Northeast Ohio Healthcare System (VANEOHS) requires continued access to specialized genomic classifier testing used to assess risk of metastasis or metastatic progression in patients with localized or advanced prostate cancer.  Decipher prostate testing is a powerful diagnostic and prognostic tool that assesses risk of prostate cancer progression within the next five years post detection, biopsy or surgical removal.  The test utilizes a genome-wide transcriptome assay to analyze the expression of 22 genes to generate the Decipher score.  Performed on existing tissue samples obtained during biopsy or surgical removal of the prostate, prior to any radiation or hormone therapy. Indicated in localized, N1, or metastatic disease.  Provides the Decipher score based on genomic characteristics of the tumor, independent of clinical and pathological factors. The score, ranging between 0 and 1, reflects tumor aggressiveness.

It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency.

This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government.

The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government.

All responses to this intent to sole source must be emailed to Thomas Bellamy: thomas.bellamy@va.gov & Samantha Jarrett: samantha.jarrett@va.gov by 4:00 p.m. EST November 12th, 2026.

View original listing